Follow
Adam S Darwich
Title
Cited by
Cited by
Year
Why has model‐informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future
AS Darwich, K Ogungbenro, AA Vinks, JR Powell, JL Reny, N Marsousi, ...
Clinical Pharmacology & Therapeutics 101 (5), 646-656, 2017
2032017
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption …
A S Darwich, S Neuhoff, M Jamei, A Rostami-Hodjegan
Current drug metabolism 11 (9), 716-729, 2010
2022010
Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans
AS Darwich, U Aslam, DM Ashcroft, A Rostami-Hodjegan
Drug Metabolism and Disposition 42 (12), 2016-2022, 2014
1942014
Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy
AS Darwich, TM Polasek, JK Aronson, K Ogungbenro, DFB Wright, ...
Annual review of pharmacology and toxicology 61, 225-245, 2021
982021
The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery
MJ Brill, A van Rongen, EP van Dongen, B van Ramshorst, EJ Hazebroek, ...
Pharmaceutical research 32, 3927-3936, 2015
712015
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism …
AS Darwich, D Pade, BJ Ammori, M Jamei, DM Ashcroft, ...
Journal of Pharmacy and Pharmacology 64 (7), 1008-1024, 2012
682012
IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results
A Margolskee, AS Darwich, X Pepin, L Aarons, A Galetin, ...
European Journal of Pharmaceutical Sciences 96, 610-625, 2017
632017
Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes
AS Darwich, K Henderson, A Burgin, N Ward, J Whittam, BJ Ammori, ...
British journal of clinical pharmacology 74 (5), 774-787, 2012
632012
Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria
K Doki, AS Darwich, N Patel, A Rostami-Hodjegan
European journal of pharmaceutical sciences 109, 111-120, 2017
522017
Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
MJE Brill, PAJ Välitalo, AS Darwich, B van Ramshorst, HPA Van Dongen, ...
CPT: pharmacometrics & systems pharmacology 5 (1), 20-30, 2016
452016
IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across …
AS Darwich, A Margolskee, X Pepin, L Aarons, A Galetin, ...
European Journal of Pharmaceutical Sciences 96, 626-642, 2017
442017
IMI–oral biopharmaceutics tools project–evaluation of bottom-up PBPK prediction success part 1: characterisation of the OrBiTo database of compounds
A Margolskee, AS Darwich, X Pepin, SM Pathak, MB Bolger, L Aarons, ...
European Journal of Pharmaceutical Sciences 96, 598-609, 2017
412017
Deconvolution and IVIVC: exploring the role of rate-limiting conditions
A Margolskee, AS Darwich, A Galetin, A Rostami-Hodjegan, L Aarons
The AAPS journal 18, 321-332, 2016
372016
Drug disposition and modelling before and after gastric bypass: immediate and controlled‐release metoprolol formulations
I Gesquiere, AS Darwich, B Van der Schueren, J de Hoon, M Lannoo, ...
British journal of clinical pharmacology 80 (5), 1021-1030, 2015
372015
What does it take to make model-informed precision dosing common practice? Report from the 1st Asian symposium on precision dosing
TM Polasek, A Rostami-Hodjegan, DS Yim, M Jamei, H Lee, H Kimko, ...
The AAPS journal 21, 1-9, 2019
352019
Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically …
A Olivares-Morales, Y Kamiyama, AS Darwich, L Aarons, ...
European Journal of Pharmaceutical Sciences 67, 32-44, 2015
332015
Evaluation of an In Silico PBPK Post‐Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine
AS Darwich, D Pade, K Rowland‐Yeo, M Jamei, A Åsberg, H Christensen, ...
CPT: pharmacometrics & systems pharmacology 2 (6), 1-9, 2013
332013
Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs
AS Darwich, K Ogungbenro, OJ Hatley, A Rostami-Hodjegan
Translational Cancer Research 6 (Suppl 10), 2017
322017
Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models
S Hansmann, A Darwich, A Margolskee, L Aarons, J Dressman
Journal of Pharmacy and Pharmacology 68 (12), 1501-1515, 2016
302016
time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment
E El‐Khateeb, AS Darwich, B Achour, V Athwal, A Rostami‐Hodjegan
Alimentary Pharmacology & Therapeutics 54 (4), 388-401, 2021
262021
The system can't perform the operation now. Try again later.
Articles 1–20